Methyl -3-Oxo-4-(2,4,5-Trifluorophenyl)Butanoate

769195-26-8

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise× that is market-oriented and realizes industrial development through R&a≤mp;D innovation and technology transformation.

key word:

Pharmaceutical technology

Category:

Related

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a larg₩e health industry finance platform company integrat ing pharmaceutical, intelligent medical, bio pharmaceutical R&™D, industrial production and sales.

The chemical reactions involved in the existing products include Foucault reaction, nit®ration reaction, sulfonation reaction, hydrogenation reaction, ∞fluorination reaction, chlorination reaction, bromination reaction, di§azotization reaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inh‍ibitor developed by Merck. In October 2006, Sitaglip≤tin phosphate Januvia was approved by FDA as the first DPP4 inh✘ibitor for the treatment of type ⅱ diabetes mellitus. The characteristics of this drug are that it≤ can stimulate insulin secretion while reducing hunger without causing weight gain. Hypoglycemia anαd edema will not occur, and it is suitable for diabetic patients with poor blood gluco∑se control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enteπrprise that is market-oriented and realizes industrial development through R&D i←nnovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most important products for t€he treatment of arthritis. It is well tolerated and has a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotrien•e receptor antagonists. In clinical application, it has good therapeutic effect on atopic asthma a&nd other types of bronchial asthma, and the market prospect is huge. In the mαajor category of asthma drugs, leukotriene receptor antagonists ha•ve the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enεterprise that is market-oriented and realizes industrial development through R&D ≈innovation and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the →second drug approved by FDA for Alzheimer's disease in the United Sta∏tes. Its treatment reaches the target dose and has low toxic and side effects. I↕t has been widely recognized by our medical community, and good t¥olerance is its biggest advantage. In October 1999, Donepezil was launched in China under the trad¥e name "Aricept", which is the main chemical drug against Alz&heimer's disease. At present, CFDA has approved a number of domestic enterprises tλo produce donepezil preparations, the main dosage forms are tablets, βcapsules, dispersive tablets, oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-♦Myers Squibb/Pfizer), a direct oral factor Xa inhibitor, >was approved for use in the 27 EU member states. The world's f♥irst drug approved to prevent venous thromboembolism (V≠TE) in adult patients undergoing elective hip or knee replacement. From June 2019 to June ↔2020, the annual sales of apixaban products overseas reach®ed about $15.4 billion, with a year-on-year growth of near<ly 32%, and the API consumption reached about 23,960 kg, w‍ith a year-on-year growth of about 28%. Compared with its main competitor, Rivaroxaban, the drug 's annual overseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-→oriented and realizes industrial development throug h R&D innovation and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Gen≥zyme. On December 29, 2004, it was approved by FDA for↔ the treatment of refractory or relapsed acute lympho¶blastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-orien​ted and realizes industrial development through R&D innovation and techno£logy transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need other sφervices, E-mail: 2880705932@qq.com